Latest updates on chronic delta hepatitis

Yıl 2016, Special Issue :2 Gastroenterology and Hepatology Viral Hepatitis, 50 - 54, 01.08.2016

Kendal Yalçın Elif Tuğba Tuncel Feyza Gündüz

https://doi.org/10.5472/MMJsi.2901.10

Öz

The hepatitis D virus was shown for the first time in 1977 byRizzetto and friends. The HDV genome and the cloning ofsequence were made in 1986. HDV is the first animal virus withcircular RNA genome which is seen only in plant viruses. HDVis an RNA virus with the known smallest viral genome in animalviruses. It is classified as Deltavirus genius depending on the typeof virus by ICTV in 1996. HDV is classified as the sole example ofdelta virus in this genus.Chronic delta hepatitis is the least common form of chronicviral hepatitis due to hepatotropic viruses. In contrast, the virusis highly pathogenic and can cause serious consequences. Today,prevalance of delta hepatitis has been shown to decrease. However,the delta hepatitis continues to be an important health problem insome parts of the world. In our country, especially in Eastern andSoutheastern Anatolia, hepatitis D is a serious and important healthproblem and still maintains its importance as a health problem. InTurkey, still there is a significant number of patients with HDVinfection despite a documented decrease in HDV infection.The recommended treatment for chronic HDV infection in thecurrent guidelines is the treatment with peginterferon alfa givenonce a week for 48 weeks. Treatment is indicated for patients whohas compensated disease with active infection. In patients withadvanced form of disease, the expected benefits of the peginterferonmust be well balanced against the potential side effects and lowresponse rate. An oral antiviral can be recommended in patientswho has high levels of serum HBV DNA. In contrast, the controlof HBV infecion does not seem to change the natural history ofHDV related disease.Keywords: Delta hepatitis, Treatment, Prognosis

Kaynakça

• Rizzetto M. Critical care options. In: Afdhal NH, Zeuzem S
• editors. Clinical Care Options, Hepatitis, Practice, Hepatitis
• Delta virus. Last Reviewed: 6/23/14 (What’s New).
• Taylor JM. Replication of the hepatitis delta virus RNA
• genome. Adv Virus Res 2009;74:103-21.
• Greco-Stewart VS, Schissel E, Pelchat M. The hepatitis
• delta virus RNA genome interacts with the human RNA
• polymerases I and III. Virology 2009;386:12-5.
• World Health Organization. Hepatitis B fact sheet 204
• (updated July 2013). Available at: http://www.who.int/
• mediacentre/factsheets/fs204/en/index.html. Accessed June
• 2014.
• Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta
• virus. Lancet 2011;378:73-85.
• Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin
• Liver Dis 2012;32:211-9.
• Farci P. Delta hepatitis: an update. J Hepatol 2003;39(suppl
• S212-S219.
• Genné D, Rossi I. Hepatitis delta in Switzerland: a silent
• epidemic. Swiss Med Wkly 2011 Mar 18.
• Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB.
• Italian Hospitals’ Collaborating Group. Evolving clinical
• landscape of chronic hepatitis B: a multicenter Italian study. J
• Med Virol 2009;81:1999-2006.
• Değertekin H, Yalcin K, Yakut M, Yurdaydin C.
• Seropositivity for delta hepatitis in patients with chronic
• hepatitis B and liver cirrhosis in Turkey: a meta-analysis.
• Liver Int 2008;28:494-8.
• Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y
• Yalniz M. Prevalence of hepatitis delta virus (HDV) infection
• in chronic hepatitis B patients in eastern Turkey: still a serious
• problem to consider. J Viral Hepat 2011;18:518-24.
• Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis
• delta virus infection in acute and chronic liver diseases in
• Turkey: An analysis of clinical studies. Turk J Gastroenterol
• 17:25-34.
• Yalçın K, Yalçın S, Büyükbayram H, et al. Kronik HDV
• infeksiyonlu hastalarda serum HBV DNA, HDV RNA
• düzeyleri ve histolojik bulguların hastalığın klinik evreleriyle ilişkisi: prospektif klinik çalışma. 25. Ulusal Gastroenteroloji
• Haftası, 2008.
• Yalçın K, Değertekin H. Etiology and clinical aspects
• of liver cirrhosis in Diyarbakır. National congress of
• Gastroenterology, Turkey, 2002.
• Bonino F, Caporaso N, Dentico P, et al. Familiar clustering
• and spreading of hepatitis delta virus infection. J Hepatol
• 1:221-6.
• Wu JC, Chen CM, Sheen IJ, et al. Evidence of transmission
• of hepatitis D virus to spouses from sequence analysis of the
• viral genome. Hepatology 1995;226:1656-60.
• Rosenblum L, Darrow W, Witte J, et al. Sexual practices
• in the transmission of hepatitis B virus and prevalence of
• hepatitis delta virus infection in female prostitutes in the
• United States. JAMA 1992;267:2477-81.
• Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D
• virus biology and disease. Prog Liver Dis 1994;12:157-75.
• Dény P. Hepatitis delta virus genetic variability: from
• genotypes I, II, III to eight major clades? Curr Top Microbiol
• Immunol 2006;307:151-71.
• Shakil AO, Hadziyannis S, Hoofnagle JH, et al. Geographic
• distribution and genetic variability of hepatitis delta virus
• genotype I. Virology 1997;234:160-7.
• Alvarado-Mora MV, Romano CM, Gomes-Gouvêa MS
• Gutierrez MF, Carrilho FJ, Pinho JR. Dynamics of hepatitis
• D (delta) virus genotype 3 in the Amazon region of South
• America. Infect Genet Evol 2011;11:1462-8.
• Rizzetto M. Hepatitis D: thirty years after. J Hepatol
• 50:1043-50.
• McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis
• B virus infection: relation of age to the clinical expression
• of disease and subsequent development of the carrier state. J
• Infect Dis 1985;151:599-603.
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.
• Hepatology 2009;50:661-2.
• Negro F, Rizzetto M. Diagnosis of hepatitis delta virus
• infection. J Hepatol 1995;22(1 suppl):136-9.
• Smedile A, Niro MG, Rizzetto M. Detection of serum HDVRNA
• by RT-PCR. Methods Mol Med 2004;95:85-93.
• Le Gal F, Gordien E, Affolabi D, et al. Quantification of
• hepatitis delta virus RNA in serum by consensus real-time
• PCR indicates different patterns of virological response to
• interferon therapy in chronically infected patients. J Clin
• Microbiol 2005;43:2363-9.
• Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative
• longitudinal evaluations of hepatitis delta virus RNA and
• hepatitis B virus DNA shows a dynamic, complex replicative
• profile in chronic hepatitis B and D. J Hepatol 2010;52:658-
• Mederacke I, Bremer B, Heidrich B, et al. Establishment of a
• novel quantitative hepatitis D virus (HDV) RNA assay using
• the Cobas TaqMan platform to study HDV RNA kinetics. J
• Clin Microbiol. 2010;48:2022-9.
• Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int
• 31:7-21.
• Fattovich G, Giustina G, Christensen E, et al. Influence of
• hepatitis delta virus infection on morbidity and mortality
• in compensated cirrhosis type B. The European Concerted
• Action on Viral Hepatitis (Eurohep). Gut 2000;46:420-6.
• Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence
• of hepatitis delta virus (HDV) infection in South London. J
• Med Virol 2008;80:277-82.
• Ji J, Sundquist K, Sundquist J. A population-based study of
• hepatitis D virus as potential risk factor for hepatocellular
• carcinoma. J Natl Cancer Inst 2012;104:790-2.
• Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J
• Viral Hepat 2005;12:2-9.
• Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon
• therapy with or without ribavirin in chronic delta hepatitis.
• Antivir Ther 2005;10:721-6.
• Calle Serrano B, Manns MP, Wedemeyer H. Hepatitis delta
• and HIV infection. Semin Liver Dis 2012;32:120-9.
• Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of
• peginterferon alpha-2b in chronic hepatitis delta: relevance
• of quantitative RT-PCR for follow-up. Hepatology
• 44:728-35.
• Mederacke I, Yurdaydin C, Dalekos GN, et al. Anti-HDV
• immunoglobulin M testing in hepatitis delta revisited
• correlations with disease activity and response to pegylated
• interferon-α2a treatment. Antivir Ther 2012;17:305-12.
• Di Martino V, Thevenot T, Colin JF, et al. Influence of
• HIV infection on the response to interferon therapy and the
• long-term outcome of chronic hepatitis B. Gastroenterology
• 123:1812-22.
• Soriano V, Puoti M, Peters M, et al. Care of HIV patients with
• chronic hepatitis B: updated recommendations from the HIVHepatitis
• B Virus International Panel. AIDS 2008;22:1399-
• Samuel D, Zignego AL, Reynes M, et al. Long-term
• clinical and virological outcome after liver transplantation
• for cirrhosis caused by chronic delta hepatitis. Hepatology
• 21:333-9.
• Burra P, Germani G, Adam R, et al. Liver transplantation
• for HBV-related cirrhosis in Europe: an ELTR study on
• evolution and outcomes. J Hepatol 2013;58:287-96.
• Lamers MH, Kirgiz ÖÖ, Heidrich B, Wedemeyer H, Drenth
• JP. Interferon-α for patients with chronic hepatitis delta: a
• systematic review of randomized clinical trials. Antivir Ther
• 17:1029-37.
• Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy
• of prenylation inhibitors against hepatitis delta virus. Clin
• Invest 2003;112:407-14.
• Chang J, Taylor JM. Susceptibility of human hepatitis
• delta virus RNAs to small interfering RNA action. J Virol
• 77:9728-31.
• Fiedler M, Kosinska A, Schumann A, et al. Prime/boost
• immunization with DNA and adenoviral vectors protects
• from hepatitis D virus (HDV) infection after simultaneous
• infection with HDV and woodchuck hepatitis virus. J Virol
• 87:7708-16.